WARF: P09185US

  • Assigned to WARF as biological material.

Antibodies to NGAL for Detection of Cancer and Kidney Damage


Michael Gould, Jill Haag

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in unique antibodies to neutrophil gelatinase-associated lipocalin (NGAL).
OVERVIEWNeutrophil gelatinase-associated lipocalin (NGAL) is a recently discovered cytokine. Because many types of cells produce NGAL in response to injury, it provides a biomarker for several chronic conditions. NGAL can be used in a diagnostic assay to detect certain types of cancer cells. It serves as a strong indicator of kidney damage, and may be useful to monitor other chronic conditions as well.
THE INVENTIONUW-Madison researchers have developed purified antibodies to NGAL. These unique antibodies can be used in immunoassays for the diagnosis and prognosis of some types of cancer, renal failure and other diseases.
  • Immunoassays for cancer, kidney damage and other chronic conditions
  • Provides unique antibodies against NGAL
For More Information About the Inventors
  • Stoesz S.P., Friedl A., Haag J.D., Lindstrom M.J., Clark G.M., and Gould M.N. 1998. Heterogeneous Expression of the Lipocalin N-gal in Primary Breast Cancers. Int. J. Cancer 79, 565-572.
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.